Latest news with #SachaLoiseau
Yahoo
a day ago
- Business
- Yahoo
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
All the resolutions proposed by the Board of Directors were adopted PARIS & BOSTON, June 05, 2025--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions. Details on the vote results are available on the Company's website. About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document. View source version on Contacts Mauna Kea Technologies investors@ NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean+33 (0)1 44 71 94 94maunakea@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business
- Business Wire
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions. Details on the vote results are available on the Company's website. About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Business Wire
21-05-2025
- Business
- Business Wire
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides an update on the safeguard proceedings initiated on March 31, 2025 1, as well as on the progress of its strategic discussions and operational developments. This announcement is part of the Company's commitment to maintaining ongoing transparency with its shareholders and partners during the ongoing process. Since the initiation of this safeguard proceedings, the Company has engaged in constructive discussions with its financial partners to identify the most appropriate options for achieving a sustainable solution to the current situation. In parallel, the Company is actively pursuing the exclusive negotiations announced on April 1 st, 2025, with a major healthcare player, aiming to finalize a licensing agreement for Cellvizio® technology in a high-potential therapeutic area. These discussions are progressing constructively and could represent a major strategic milestone for the Company's clinical and commercial development. On the operational front, Mauna Kea Technologies is experiencing strong momentum with its CellTolerance franchise. The symbolic milestone of 1,500 procedures has been surpassed, demonstrating the growing adoption of the technology. Several new accounts have recently been onboarded, including prestigious institutions that form a solid foundation for future growth. Among them, a leading center in the United States has already performed over 100 procedures in just a few months and continues to show an upward trend in usage. The Company plans to continue updating on these clinical and commercial advancements in the coming weeks. Finally, Mauna Kea Technologies is actively engaged with several investors to secure the financial visibility required for the safeguard proceedings and the finalization of licensing agreement. These discussions aim to provide the Company with the resources required to execute its long-term growth strategy. Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated: "We are navigating this transition period with full determination and remain strongly committed to equipping the Company for future growth. Our commercial outlook is becoming more tangible each day, both for CellTolerance and our pancreatic cyst application, which are increasingly supported by clinical data and a clear enthusiasm among physicians and patients. The safeguard proceedings provide us with a protective framework ideal for negotiating with our stakeholders and preparing for the Company's redeployment on solid foundations. I am very pleased with the dedication of our teams and am fully committed to shaping a new chapter of strong value creation for the Company. Cellvizio is proving its relevance more than ever today, offering a unique opportunity to improve care for millions of patients while reducing healthcare system costs." *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Business Wire
06-05-2025
- Health
- Business Wire
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week ® 2025
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced completion of the largest annual pancreatic cyst consortium held at the Digestive Disease Week ® (DDW) Conference in San Diego, California, on Monday May 5, 2025. The detailed program is available on the Mauna Kea Technologies website at the following link: The consortium brought together more than 75 physicians from across the United States with a focus on cutting-edge advancements in the diagnosis, classification, risk stratification, and treatment of pancreatic cystic lesions and pancreatic cancer. Attendance tripled compared to the 2024 meeting, reflecting the growing interest among the medical community in this field. Central to the discussions was the growing impact of endoscopic ultrasound with Cellvizio needle-based Confocal Laser Endomicroscopy (EUS-nCLE) in enabling earlier and more accurate diagnoses and clinical decisions before any therapy begins, with the goal of increasing non-surgical treatment options. The consortium was led by Dr. Somashekar (Som) Krishna, MD, MPH, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center and principal investigator of the CLIMB 1 study. It was co-sponsored by 9 leading medical device and pharmaceutical products companies, demonstrating strong cross-industry commitment to advancing care for the millions of patients affected by pancreatic cystic lesions worldwide. "This year's consortium marks a turning point in how the medical community and the industry approach pancreatic cyst management and treatment,' said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. 'Bringing together more than 75 top physicians and 9 committed industry partners shows that the ecosystem around EUS-nCLE, RFA 2, and AI is maturing rapidly - and with it, our ability to change the standard of care for patients facing pancreatic lesions. A clear momentum is building around this application, driven by the recent endorsement of nCLE in European clinical guidelines and the surge of interest we're now seeing in the United States at DDW. We're proud to help lead this transformation and deeply grateful to our collaborators and clinical pioneers who are making it possible. With Cellvizio, we are targeting one of the largest unmet clinical issues in gastroenterology - and changing the trajectory for many patients at risk of pancreatic cancer.' *** About Pancreatic Cysts The prevalence of pancreatic cystic lesions in the adult asymptomatic population ranges from 2.4% to 24.3%. The large majority of pancreatic cystic lesions are discovered through incidental imaging, and it is estimated that 40% of cysts with no risk of carcinogenesis are operated on unnecessarily. More accurate classification methods, including risk stratification, are therefore needed earlier in the patient's diagnostic workup. Conventional diagnostic testing involves performing an endoscopic ultrasound (EUS) and then collecting and testing the cyst fluid through fine needle aspiration (FNA). In some advanced facilities, next generation sequencing (NGS) of cellular DNA may be performed to provide additional data. Although most facilities employ a combination of a range of conventional diagnostic methods, sensitivity, specificity, and accuracy remain insufficient, potentially exposing patients to misclassified cysts and unneeded surgical procedures. About Digestive Disease Week ® Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW was an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document. _________________________________ 1 NCT03492151 2 Radiofrequency Ablation
Business Wire
28-04-2025
- Health
- Business Wire
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week ® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio ® in Key Indications
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced another milestone year at the Digestive Disease Week ® (DDW) Conference, being held from May 3-6, 2025 in San Diego, California with the presentation of at least 8 abstracts supporting the clinical value of Cellvizio ® in key indications. These abstracts focus on pancreatic cystic lesions and pancreatic cancer, food intolerance, artificial intelligence, and other gastrointestinal disorders. Studies and presentations highlight how the use of Cellvizio ® directly impacts patient management and positive outcomes. Members of Mauna Kea's executive team will be present at DDW and meeting with physicians, industry partners, and societies, and welcome the opportunity to discuss the Company's recent achievements and future opportunities as announced in recent press releases. "Each year, DDW is a not-to-be-missed meeting bringing the entire gastroenterology healthcare community together, and we are proud yet again to have such a wide range of independent scientific abstracts and data about Cellvizio on display, especially in areas which have significant unmet patient needs,' said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. 'Cellvizio's role in the accurate classification and risk stratification of pancreatic cysts is advancing the entire field forward for the management of patients at risk of pancreatic cancer. Moreover, the body of evidence for food intolerance identification and management has grown substantially, building a large opportunity for CellTolerance ® growth.' Highlighted featured presentations: Saturday, May 3 12:30pm-1:30pm Artificial Intelligence Advances Digital Pathomics for Confocal Endomicroscopy-Guided Diagnosis of Pancreatic Cysts 12:30pm-1:30pm Intracystic Capillary Morphology as a Novel Approach to Risk Stratification of Intraductal Papillary Mucinous Neoplasms In Confocal Endomicroscopy: Limitations of Human Performance and Insights from Artificial Intelligence 3:00pm-3:15pm Confocal Laser Endomicroscopy Captures Local, Food-Induced Reactions at the Level of the Duodenal Mucosa in Functional Dyspepsia, That Cannot Be Translated into Permeability Alterations or Changes in Mast Cell Activation Ex Vivo 4:30pm-4:45pm Targeted Elimination Diet in Eosinophilic Esophagitis Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy: Results from a Pilot Trial Sunday, May 4 8:12am-8:19am Towards Automating Risk Stratification of Intraductal Papillary Mucinous Neoplasms: Artificial Intelligence Advances Beyond Human Expertise with Confocal Laser Endomicroscopy Monday, May 5 8:42am-8:49am Is It Time to Refine Our Standards? Insights From a Multicenter Prospective Study on Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy (EUS-nCLE) For Diagnosing Pancreatic Cystic Lesions 10:30am-10:45am Effects of a Multimodal Treatment Approach in Patients with Longstanding Irritable Bowel Syndrome on Symptom Relief and Barriere Integrity Targeted by Confocal Laser Endomicroscopy: An Exploratory Prospective Observational Clinical Trial 12:30pm-1:30pm Real-Time Intestinal Barrier Assessment by Endocytoscopy and Confocal Laser Endomicroscopy Uniquely Correlates with Multiple Barrier Protein Expression and Reflects the Gut-Brain Axis About Digestive Disease Week ® Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
